Inclusion Criteria:

          -  Patients with a confirmed diagnosis of BCR/ABL+ CML in chronic phase

        Documented chronic phase CML must meet all the following criteria:

        < 15% blasts in peripheral blood < 30% blasts plus promyelocytes in peripheral blood < 20%
        basophils in the peripheral blood

          -  100 x 109/L (≥ 100,000/mm3) platelets

               -  Age ≥18

               -  ECOG performance status of 0-2

               -  Evidence of typical BCR-ABL transcripts which are amenable to standardized RQ-PCR

               -  Adequate end organ function as defined by:

        Total bilirubin < 1.5 x ULN (ULN = upper limit of normal in a local institution lab).

        Does not apply to patients with isolated hyperbilirubinemia (e.g., Gilbert's disease) grade
        < 3 SGOT (AST) and SGPT (ALT) ≤ 3 x ULN Serum amylase and lipase ≤ 2 x ULN Alkaline
        phosphatase ≤ 2.5 x ULN Serum creatinine < 1.5 x ULN

          -  Having completed the QoL baseline evaluation (i.e., before randomization)

          -  Written informed consent prior to any study procedures.

        Exclusion Criteria:

          -  Expression of any atypical BCR-ABL transcripts, instead of the classical P210-encoding
             type with the e13a2 or the e14a2 junction at screening.

          -  Previous treatment with BCR-ABL inhibitors for a period longer than 1 month.

          -  Previous anticancer agents (hydroxyurea, anagrelide, interferon) for CML for a time
             longer than three months.

          -  Poorly controlled diabetes mellitus (defined as HbA1c >8%).

          -  Prior documented history of coronary heart disease, including myocardial infarction,
             coronary bypass, coronary stent, and symptomatic angina:

        LVEF <45% or below the institutional lower limit of the normal range (whichever ishigher)
        Complete left bundle branch block Right bundle branch block plus left anterior or posterior
        hemiblock Use of a ventricular-paced pacemaker Congenital long QT syndrome or a known
        family history of long QT syndrome History of or presence of clinically significant
        ventricular or atrial tachyarrhythmias

          -  Atrial fibrillation or flutter

          -  Clinically significant resting bradycardia (< 50 beats per minute)

          -  QTc > 450 msec on the average of three serial screening ECGs (using the QTcF formula).
             If QTcF > 450 msec and electrolytes are not within normal ranges, electrolytes should
             be corrected and the patient re-tested History or clinical signs of myocardial
             infarction within 12 months of study entry History of unstable angina within 12 months
             of study entry Other clinically significant heart disease (e.g. congestive heart
             failure)

               -  Uncontrolled hypertension is not a heart disease.

               -  History of peripheral arterial occlusive disease.

               -  History of acute pancreatitis within 12 months of study entry, or a past medical
                  history of chronic pancreatitis.

               -  Patients actively receiving therapy with strong CYP3A4 inhibitors and/or inducers
                  which cannot be either discontinued or switched to a different medication prior
                  to starting study drug.

               -  Patients who are currently receiving treatment with any medications that have the
                  potential to prolong the QT interval and for which cannot be either safely
                  discontinued or switched to a different medication prior to starting study drug.